Michael Gerometta
Chief Technology OfficerDr. Michael Gerometta, also known as Mike, Ph.D is Chief Technology Officer of Ceryvyn Therapeutics Limited (formerly known as Opthea Limited) from 2026. He had been Head of Head of Chemistry, Manufacturing and Controls Development at Ceryvyn Therapeutics Limited (formerly known as Opthea Limited) since December 2008 until 2024. Dr. Gerometta has over many years of experience in the Australian biotechnology industry, working with numerous contract manufacturing organizations overseas and locally in all facets of translational CMC from concept through to Phase 2 studies. Dr. Gerometta has been with Circadian since December 2008 and is principally responsible for the outsourcing of Vegenics’ research and cGMP manufacturing activities. He has many years’ experience in the Australian biotechnology industry, including as the Chief Operating Officer of Q-Gen, QIMR’s translational research, manufacturing arm. Dr. Gerometta served as Director of Research & Development for Agenix Ltd., until March 31, 2008. He has also spent many years at Agen Biomedical, occupying a variety of positions and roles, including as Research and Product Development Director. In this role he was responsible for the chemistry, manufacturing and controls (CMC), pre-clinical program and patent management for Agen’s ThromboView® project, a blood clot imaging agent. Previously, he has worked at Biotech Australia, Sydney and together with earlier positions at Agen, developed numerous successful immunodiagnostic assays for the medical, veterinary and food industries across various diagnostic platforms for the laboratory and point-of-care. He was awarded his PhD in biotechnology from the Queensland University of Technology and has a Bachelor of Science degree in chemistry from the University of Technology in Sydney.
Positions
- Company NameCeryvyn Therapeutics LimitedStock CodeCYVNYPositionChief Technology OfficerColleagues
- JMJeremy Max LevinExecutive Chair & CEO
- HGHamish GeorgeCFO & Joint Company Secretary
- SMStuart MudgeChief Operating Officer
- RWRebbecca WilcoxSenior VP of Preclinical and Translational Science
- LBLawrence B. GozlanIndependent Non-Executive Director
- KEKatherine Ellen-Danielle ConnellIndependent Non-Executive Director
- FXFrancis X. MccormackCo-Chair of Scientific Advisory Board
- DYDeborah YatesCo-Chair of Scientific Advisory Board
